Clinical Pharmacokinetics in Kidney Disease Application to Rational Design of Dosing Regimens

被引:53
作者
Roberts, Darren M. [1 ,3 ,4 ]
Sevastos, Jacob [2 ,5 ]
Carland, Jane E. [1 ,5 ]
Stocker, Sophie L. [1 ,5 ]
Lea-Henry, Tom N. [3 ,6 ]
机构
[1] St Vincents Hosp, Dept Clin Pharmacol & Toxicol, Victoria St, Darlinghurst, NSW 2010, Australia
[2] St Vincents Hosp, Dept Nephrol & Renal Transplantat, Darlinghurst, NSW, Australia
[3] Canberra Hosp, Dept Renal Med, Woden, ACT, Australia
[4] Australian Natl Univ, Med Sch, Acton, ACT, Australia
[5] Univ New South Wales, Dept Med, St Vincents Clin Sch, Sydney, NSW, Australia
[6] John Hunter Hosp, Nephrol & Transplantat Unit, Newcastle, NSW, Australia
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2018年 / 13卷 / 08期
关键词
CRITICALLY-ILL PATIENTS; DIALYSIS-ASSOCIATED PERITONITIS; RENAL REPLACEMENT THERAPY; EXTRACORPOREAL TREATMENTS; HOSPITALIZED-PATIENTS; DRUG-METABOLISM; DOSE ADJUSTMENT; RECOMMENDATIONS; IMPAIRMENT; CREATININE;
D O I
10.2215/CJN.05150418
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
A change in pharmacokinetics can alter drug exposure and predispose the patient to either over- or underdosing, potentially resulting in adverse drug reactions or therapeutic failure. Kidney disease is characterized by multiple physiologic effects, which induce clinically significant changes in pharmacokinetics. These vary between individuals and may be quantitated in certain instances. An understanding of pharmacokinetic concepts is, therefore, important for a rational approach to the design of drug dosing regimens for the delivery of personalized medical care. Whether kidney disease is acute or chronic, drug clearance decreases and the volume of distribution may remain unchanged or increase. AKI is defined by dynamic changes in kidney function, which complicates attempts to accurately quantify drug clearance. In contrast, changes in drug clearance progress more slowly with CKD. In general, kidney replacement therapies increase drug clearance, but the extent to which this occurs depends on the modality used and its duration, the drug's properties, and the timing of drug administration. However, the changes in drug handling associated with kidney disease are not isolated to reduced kidney clearance and an appreciation of the scale of potential derangements is important. In most instances, the first dose administered in patients with kidney disease is the same as in patients with normal kidney function. However, in some cases, a higher (loading) initial dose is given to rapidly achieve therapeutic concentrations, followed by a lower maintenance dose, as is well described when prescribing anti-infectives to patients with sepsis and AKI. This review provides an overview of how pharmacokinetic principles can be applied to patients with kidney disease to personalize dosage regimens. Patients with kidney disease are a vulnerable population and the increasing prevalence of kidney disease means that these considerations are important for all prescribers.
引用
收藏
页码:1254 / 1263
页数:10
相关论文
共 46 条
[1]  
[Anonymous], 2010, PHARM PAT IMP REN FU
[2]   Septic acute kidney injury in critically ill patients: Clinical characteristics and outcomes [J].
Bagshaw, Sean M. ;
Uchino, Shigehiko ;
Bellomo, Rinaldo ;
Morimatsu, Hiroshi ;
Morgera, Stanislao ;
Schetz, Miet ;
Tan, Ian ;
Bouman, Catherine ;
Macedo, Ettiene ;
Gibney, Noel ;
Tolwani, Ashita ;
Oudemans-van Straaten, Heleen M. ;
Ronco, Claudio ;
Kellum, John A. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 2 (03) :431-439
[3]   DIHYDROCODEINE IN RENAL-FAILURE - FURTHER EVIDENCE FOR AN IMPORTANT ROLE OF THE KIDNEY IN THE HANDLING OF OPIOID DRUGS [J].
BARNES, JN ;
WILLIAMS, AJ ;
TOMSON, MJF ;
TOSELAND, PA ;
GOODWIN, FJ .
BRITISH MEDICAL JOURNAL, 1985, 290 (6470) :740-742
[4]   Efficacy of antibiotic therapy for peritoneal dialysis-associated peritonitis: a proportional meta-analysis [J].
Barretti, Pasqual ;
Pereira Doles, Joao Vitor ;
Pinotti, Douglas Goncalves ;
El Dib, Regina .
BMC INFECTIOUS DISEASES, 2014, 14
[5]   Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers [J].
Benvenuto, Mark ;
Benziger, David P. ;
Yankelev, Sara ;
Vigliani, Gloria .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (10) :3245-3249
[6]   The influence of acute kidney injury on antimicrobial dosing in critically ill patients: are dose reductions always necessary? [J].
Blot, Stijn ;
Lipman, Jeffrey ;
Roberts, Darren M. ;
Roberts, Jason A. .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2014, 79 (01) :77-84
[7]   Principles and Operational Parameters to Optimize Poison Removal with Extracorporeal Treatments [J].
Bouchard, Josee ;
Roberts, Darren M. ;
Roy, Louise ;
Ouellet, Georges ;
Decker, Brian S. ;
Mueller, Bruce A. ;
Desmeules, Simon ;
Ghannoum, Marc .
SEMINARS IN DIALYSIS, 2014, 27 (04) :371-380
[8]   Extracorporeal Treatment for Metformin Poisoning: Systematic Review and Recommendations From the Extracorporeal Treatments in Poisoning Workgroup [J].
Calello, Diane P. ;
Liu, Kathleen D. ;
Wiegand, Timothy J. ;
Roberts, Darren M. ;
Lavergne, Valery ;
Gosselin, Sophie ;
Hoffman, Robert S. ;
Nolin, Thomas D. ;
Ghannoum, Marc .
CRITICAL CARE MEDICINE, 2015, 43 (08) :1716-1730
[9]   Can changes in renal function predict variations in β-lactam concentrations in septic patients? [J].
Casu, Giuseppe Stefano ;
Hites, Maya ;
Jacobs, Frederique ;
Cotton, Frederic ;
Wolff, Fleur ;
Beumier, Marjorie ;
De Backer, Daniel ;
Vincent, Jean-Louis ;
Taccone, Fabio Silvio .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 42 (05) :422-428
[10]   PHARMACOKINETICS OF CREATININE IN MAN AND ITS IMPLICATIONS IN MONITORING OF RENAL-FUNCTION AND IN DOSAGE REGIMEN MODIFICATIONS IN PATIENTS WITH RENAL-INSUFFICIENCY [J].
CHIOU, WL ;
HSU, FH .
JOURNAL OF CLINICAL PHARMACOLOGY, 1975, 15 (5-6) :427-434